The Whens and Whys of Top Biotech M&A Deals, page-16

I once again make reference to another brilliant post by "hottod"
From "hottod's" post # 75308697 I hereafter quote the following:

Nontheless, one would think that more than one pharma focused on neurology and/or rare diseases might be keen to position itself as the global leader in neurodevelopmental diseases.
The list could well include the likes of Roche, Novartis, Biogen, Pfizer, Takeda, BMS, Sanofi, UCB, Ipsen and, of course, Acadia.
END OF QUOTE
I had a look at different sizes of those potential "take-over candidates" - as - IMO - size does matter in terms of money available to purchase an additional segment, i.e. "worldwide leader for neurodevelopmental diseases"...
I cannot absolutely guarantee that all the hereafter mentioned turnover figures for 2023 are correct. But I have put the different companies mentioned by "hottod" in descending order of turnovers made in 2023 (all expressed in US$ billion !)
1) Roche 58.7
2) Pfizer 58.5
3) Sanofi 50.3
4) Novartis 46.7
5) BMS 45.0
6) Takeda 29.8
7) Biogen 9.8
8) UCB 5.7
9) Ipsen 3.7
10) ACADIA Less than 1 billion !

Personally, I would not like Neuren to go through lengthy Phase III trials on their own but rather look for a suitable company that can make a decent enough take-over offer. But everyone's personal views are of course different in this respect.

All the best to all NEU holders and buyers.

wasa